Videos

Getting to the heart of NAFLD/NASH – the CVD perspective

getting-to-the-heart-of-nafld-nash–the-cvd-perspective
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
Read MoreGetting to the heart of NAFLD/NASH – the CVD perspective

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

Prof. Kenneth Cusi
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreThe role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES